• Eugenia Lissarrague, María Sol Fregeiro, Yemile Binstok, Camila Barla, Manuel Cavani, Felipe Frachia, Sabrina Ranero, Liliana Servente, and Eloísa Riva.
• Universidad de la República, Montevideo, Uruguay.
• Rev Med Chil. 2022 Feb 1; 150 (2): 199-205.

Background18F-fluorodesoxyglucose positron emission tomography/ computed tomography (PET-CT) has a high sensitivity and specificity to detect medullary and extramedullary lesions in multiple myeloma (MM).AimTo describe the findings of PET-CT in extramedullary multiple myeloma (EMM) at diagnosis and at relapse, and correlate its results with clinical variables, response to treatment and survival.Materials And MethodsReview of medical records and PET-CT reports of 39 patients with multiple myeloma (MM) who had at least one PET-CT study, treated between January 1, 2015, and January 1, 2019 at a clinical hospital.ResultsThe Standard Uptake Values for each hypermetabolic lesion were not described in PET-CT reports. Fifteen patients had an EMM and in eight, without a previous clinical suspicion, PET-TC lead to the diagnosis. The mortality rate in the 39 patients with MM was 46%. Sixty seven percent of deaths occurred in patients with EMM.ConclusionsPET-TC was useful to diagnose EMM. However, a standardization in PETCT reports would be required to unify criteria. As previously reported, EMM had a greater aggressiveness and lower survival.

11 keywords...

hide…